Cytokine-producing function of circulating neutrophils during renal carcinogenesis: a case–control study

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Cytokines produced by neutrophils may determine their pro- or antitumor activity, thereby contributing either to inhibition or progression of the tumor process.

AIM: This work aimed to evaluate the cytokine-producing function of circulating neutrophils during renal carcinogenesis.

METHODS: Circulating neutrophils were studied in patients with histologically verified early-stage renal cancer (stage I, n = 30) and advanced-stage disease (stage III, n = 30), as well as in conditionally healthy donors (control group, n = 30). Concentrations of monocyte chemoattractant protein-1 (MCP-1) and interleukin-2 (IL-2) (pg/mL) in neutrophil supernatants were determined by enzyme-linked immunosorbent assay. Gene expression of MCP-1 and IL-2 in neutrophils was assessed using quantitative polymerase chain reaction. Data are presented as median (Me) and interquartile range (Q1–Q3). Statistical analysis was performed using Statistica 13 and Jamovi 2.3.28. Differences were assessed using the Mann–Whitney U test (p < 0.05). Correlation analysis was performed using the Spearman coefficient. Event probability was evaluated by odds ratio with 95% confidence intervals. A differential diagnostic model was constructed using binary logistic regression. Sensitivity and specificity were assessed by ROC curve analysis within the regression model. Predictive model performance was evaluated using the area under the ROC curve (AUC).

RESULTS: A significant decrease in MCP-1 levels in neutrophil supernatants after 30 and 60 minutes of incubation was observed at stage III renal cancer compared with stage I, confirmed by an inverse correlation between MCP-1 levels and disease stage (r = −0.456; p = 0.015). At stage I renal cancer, IL-2 levels increased significantly after 30 minutes of incubation compared with controls under both spontaneous (p = 0.007) and induced conditions (p = 0.001). IL-2 gene expression and IL-2 production in neutrophils increased with renal cancer progression (p = 0.01). A direct correlation was observed between IL-2 gene expression in neutrophils and disease stage (r = 0.671; p = 0.001). In univariate logistic regression analysis, IL-2 gene expression in neutrophils demonstrated statistical significance for differentiation between early and advanced renal cancer stages (OR 0.156; 95% CI 0.047–0.525; p = 0.003). The model AUC was 0.932 (sensitivity, 0.938; specificity, 0.750). With renal cancer progression, IL-2 gene expression increased (R2 = 0.504; χ2 = 38.5; p = 0.001).

CONCLUSION: At the early stage of renal cancer, neutrophils exert their antitumor potential via enhanced MCP-1 secretion. During renal cancer progression, increased IL-2 secretion confers protumor properties on circulating neutrophils.

Full Text

Restricted Access

About the authors

Ilseya R. Myagdieva

Ulyanovsk State University

Author for correspondence.
Email: ilseya2015@yandex.ru
ORCID iD: 0000-0002-3908-0840
SPIN-code: 1240-5547

Senior Lecturer, Depart. of Physiology and Pathophysiology

Russian Federation, Ulyanovsk

Tatyana V. Abakumova

Ulyanovsk State University

Email: taty-abakumova@yandex.ru
ORCID iD: 0000-0001-7559-5246
SPIN-code: 8564-4253

Dr. Sci. (Biology), Assistant Professor

Russian Federation, Ulyanovsk

Dinara R. Dolgova

Ulyanovsk State University

Email: dolgova.dinara@yandex.ru
ORCID iD: 0000-0001-5475-7031
SPIN-code: 7093-3564

Cand. Sci. (Biology), Assistant Professor

Russian Federation, Ulyanovsk

Tatyana P. Gening

Ulyanovsk State University

Email: Naum-53@yandex.ru
ORCID iD: 0000-0002-5117-1382
SPIN-code: 7285-8939

Dr. Sci. (Biology), Professor

Russian Federation, Ulyanovsk

Albert N. Topchyan

Ulyanovsk State University

Email: albert.topchyan.98@mail.ru
ORCID iD: 0009-0007-9088-0580
SPIN-code: 5271-4542

student, T.Z. Biktimirov Faculty of Medicine

Russian Federation, Ulyanovsk

References

  1. Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. doi: 10.1186/s12943-021-01316-8 EDN: SWHFKM
  2. Ridge CA, Pua BB, Madoff DC. Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 2014;31(1):3–8.
  3. Li P, Znaor A, Holcatova I, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Europeanurology. 2015;67(6):1134–1141. doi: 10.1016/j.eururo.2014.11.001 EDN: SSVBST
  4. Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402–1410. doi: 10.1016/j.imbio.2013.06.003
  5. Ohms M, Möller S, Laskay T. An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro. Front Immunol. 2020;(11):532. doi: 10.3389/fimmu.2020.00532 EDN: YUXOIA
  6. Chudilova GA, Nesterova IV, Kovaleva SV, Lomtatidzel V. Regulatory cytokine effects in vitro on the phenotype of subpopulations CD62L+CD63−, CD62L+CD63+ and microbicidal activity of neutrophilic granulocytes in patients with colorectal cancer. RUDN Journal of Medicine. 2020;24(4):304–314. doi: 10.22363/2313-0245-2020-24-4-304-314 EDN: UNWFAI
  7. Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol. 2018;36:411–433. doi: 10.1146/annurev-immunol-042617-053352
  8. Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBio Medicine. 2023;90:104539. doi: 10.1016/j.ebiom.2023.104539 EDN: QPLIFU
  9. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153–165. doi: 10.1016/j.immuni.2010.08.004
  10. Minns D, Smith KJ, Hardisty G, et al. The Outcome of Neutrophil-T Cell Contact Differs Depending on Activation Status of Both Cell Types. Front Immunol. 2021;12:633486. doi: 10.3389/fimmu.2021.633486 EDN: XCRBZK
  11. Mitchem JB, DeNardo DG. Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes. Breast Cancer Res. 2012;14(4):315. doi: 10.1186/bcr3149 EDN: ZBBDNU
  12. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128–1141. doi: 10.1158/0008-5472.CAN-12-2731
  13. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;5:508. doi: 10.3389/fimmu.2014.00508
  14. Fridlender ZG, Buchlis G, Kapoor V, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010;70(1):109–118. doi: 10.1158/0008-5472.CAN-09-2326 EDN: NYRJRT
  15. Li M, Knight DA, A Snyder L, et al. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology. 2013;2(7):e25474. doi: 10.4161/onci.25474
  16. Lavender N, Yang J, Chen SC, et al. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. BMC Cancer. 2017;17(1):88. doi: 10.1186/s12885-017-3074-2 EDN: FDLGTU
  17. Maskarinec SA, McKelvy M, Boyle K, et al. Neutrophil functional heterogeneity is a fixed phenotype and is associated with distinct gene expression profiles. J Leukoc Biol. 2022;112(6):1485–1495. doi: 10.1002/JLB.4A0322-164R EDN: AHSPED
  18. Kokinos EK, Tsymbal SA, Galochkina AV, et al. Inhibition of Cyclin-Dependent Kinases 8/19 Restricts Bacterial and Virus-Induced Inflammatory Responses in Monocytes. Viruses. 2023;15(6):1292. doi: 10.3390/v15061292 EDN: YENUUQ
  19. Cvikl B, Lussi A, Moritz A, et al. Sterile-filtered saliva is a strong inducer of IL-6 and IL-8 in oral fibroblasts. Clin Oral Investig. 2015;19(2):385–399. doi: 10.1007/s00784-014-1232-3 EDN: OIZFRU
  20. IravaniSaadi M, Salami J, Abdi H, et al. Expression of interleukin 1, interleukin 27, and TNF α genes in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy: A case-control study. Health Sci Rep. 2022;5(4):e701. doi: 10.1002/hsr2.701 EDN: QTAGTG
  21. Powell DR, Huttenlocher A. Neutrophils in the Tumor Microenvironment. Trends Immunol. 2016;37(1):41–52. doi: 10.1016/j.it.2015.11.008 EDN: VFUINN
  22. Wu L, Saxena S, Awaji M, Singh RK. Tumor-Associated Neutrophils in Cancer: Going Pro. Cancers. 2019;11(4):564. doi: 10.3390/cancers11040564 EDN: XARMLT
  23. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–225. doi: 10.1038/nature10138
  24. Huang B, Lei Z, Zhao J, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252(1):86–92. doi: 10.1016/j.canlet.2006.12.012
  25. Li M, Knight DA, A Snyder L, et al. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology. 2013;2(7):e25474. doi: 10.4161/onci.25474
  26. Granot Z, Henke E, Comen EA, et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300–314. doi: 10.1016/j.ccr.2011.08.012
  27. Arakaki R, Yamasaki T, Kanno T, et al. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. Cancer Med. 2016;5(10):2920–2933. doi: 10.1002/cam4.886 EDN: VKOXFG
  28. Wu K, Lin K, Li X, et al. Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020;11:1731. doi: 10.3389/fimmu.2020.01731 EDN: NHMAOT
  29. Shen J, Wang R, Chen Y, et al. Prognostic significance and mechanisms of CXCL genes in clear cell renal cell carcinoma. Aging (Albany NY). 2023;15(16):7974–7996. doi: 10.18632/aging.204922 EDN: SPAZDO

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. IL-2 and MCP-1 gene expression in circulating neutrophils at different stages of renal cancer. *, significant differences compared with the control group; #, significant differences compared with stages I–II renal cancer.

Download (60KB)
Indexing metadata
3. Fig. 2. ROC curve for the regression model differentiating early-stage and advanced-stage renal cancer based on IL-2 gene expression in circulating neutrophils.

Download (56KB)
Indexing metadata

© 2026 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07